DBVT — DBV Technologies S.A.

Nasdaq · Health Care · Biotechnology · CIK 1613780 ·
Last close
$17.42
Market Cap
$1.03B
52W High
$23.04
52W Low
$15.61
ADV30
246,277
Next earnings
2026-07-29
DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products in France. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow's milk protein allergy and eosinophilic esophagitis. The company's earlier stage research programs include celiac disease. In addition, the company develops Viaskin technology platform, a platform to potentially treat food allergy. It has a collaboration with Nestlé Health Science to develop MAG1C, a ready-to-use atopy patch test for the diagnosis of non-IgE mediated CMPA in infants and toddlers. DBV Technologies S.A. was incorporated in 2002 and is headquartered in Châtillon, France.

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGrossProfit OpIncomeNetIncomeAssets CashLiabilities
Mar 2026 0 -47,900,000 -47,600,000 266,400,000 229,200,000 58,500,000
Dec 2025 0 -45,048,000 -44,829,000 233,718,000 194,167,000 64,948,000
Sep 2025 0 -34,277,000 -33,164,000 110,495,000 69,837,000 57,641,000
Jun 2025 0 -41,110,000 -41,875,000 143,429,000 103,207,000 57,205,000

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$-150,483,000
Investing CF
$-1,169,000
Financing CF
$365,082,000
CapEx
$-928,000
Dividends Paid
Buybacks
$-152,000
EPS Diluted TTM
$-4.60
As of
2026-05-10

Balance + Analyst (yfinance extras)

Retained Earnings
$-440,700,000
Inventory
Receivables
$15,100,000
ST Investments
EBIT TTM
$-168,335,000
Pretax Income TTM
$-166,777,000
Interest Exp TTM
Analysts
6

Yahoo Snapshot (yfinance, live)

Total Revenue
$5,736,000
EBITDA
$-165,162,000
Free Cash Flow
$-87,206,000
Enterprise Value
$807,569,792
Total Cash
$229,200,000
Total Debt
$6,100,000
Shares Out
59,186,686
Trailing EPS
$-4.50
Book Value
$3.52
ROE
-158.9%
ROA
-66.4%
Div Yield

Annual Trend (SEC EDGAR, last 4y)

Revenues vs Net Income (last 4y)

FY endRevenuesOpIncome NetIncomeAssetsLiabilities EquityOCF
Dec 2025 0 -147,054,000 -146,947,000 233,718,000 64,948,000 -121,181,000
Dec 2024 0 -116,590,000 -113,918,000 65,658,000 38,271,000 -104,474,000
Dec 2023 0 -76,433,000 -72,726,000 182,986,000 42,799,000 -79,653,000
Dec 2022 0 -96,631,000 -96,274,000 246,518,000 52,065,000 -55,666,000

TTM Snapshot

Revenues TTM
$3,533,000
NetIncome TTM
$-49,852,000
OpCashFlow TTM
$0
Assets (Latest)
$65,658,000
Forward EPS
$-0.49

Peers — same industry

TickerNameMarket CapLastDaily %
COAG Hemab Therapeutics Holdings, Inc. $1.17B $24.98
MGTX MeiraGTx Holdings plc $888.13M $9.59
DBVTF DBV Technologies S.A. $1.26B $4.26
CGEM Cullinan Therapeutics, Inc. $841.98M $13.70
IMTX Immatics N.V. $1.28B $9.38

News headlines (Yahoo Finance, 1h cache)

DBV Technologies (DBVT) Soars 5.3%: Is Further Upside Left in the Stock?
2026-06-15 11:59 · Yahoo
European Equities Traded in the US as American Depositary Receipts Increase in Friday Trading; Rise for Week
2026-06-12 15:14 · Yahoo
DBV Technologies Revises Participation in the Goldman Sachs 47th Annual Global Healthcare Conference
2026-06-09 11:00 · Yahoo
DBV Technologies to Present New Positive Data from VITESSE Study and Preview Recently Initiated THRIVE Study at the EAACI Congress 2026
2026-06-08 20:35 · Yahoo
DBV Technologies to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference
2026-06-05 20:30 · Yahoo
European Equities Traded in the US as American Depositary Receipts Decline in Friday Trading; Rise for Week
2026-06-05 15:06 · Yahoo
European Equities Traded in the US as American Depositary Receipts Rise in Thursday Trading
2026-06-04 15:08 · Yahoo
Information Regarding the Total Number of Voting Rights and Total Number of Shares of the Company as of May 31, 2026
2026-06-03 20:31 · Yahoo
DBV Technologies Announces the Results of its 2026 Combined General Meeting
2026-06-03 20:30 · Yahoo
DBV Technologies Announces First Participant Screened in THRIVE Phase 2 Study of the VIASKIN® Peanut Patch in Infants ages 6 through 12 Months with Peanut Allergy
2026-06-02 23:40 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.